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Abstract A series of diethyl 2-(4,5-dimethoxycarbonyl-
1H-1,2,3-triazol-1-yl)alkylphosphonates was synthesised
from x-azidoalkylphosphonates and dimethyl acetylene-
dicarboxylate and was further transformed into the
respective diamides, dihydrazides, and 5,6-dihydro-1H-
[1,2,3]triazolo[4,5-d]pyridazine-4,7-diones as phosphonate
analogues of acyclic nucleosides having nucleobases
replaced with substituted 1,2,3-triazoles. All compounds
containing P–C–C–triazole or P–C–C–CH2–triazole moie-
ties exist in single conformations in which the
diethoxyphosphoryl and substituted 1,2,3-triazolyl or
substituted (1,2,3-triazolyl)methyl groups are oriented anti.
All phosphonates were evaluated in vitro for activity
against a variety of DNA and RNA viruses. None of the
compounds were endowed with antiviral activity. They
were not cytostatic at 100 lM.
Keywords Cycloadditions  Cyclizations  Heterocycles 
NMR spectroscopy  Conformation
Introduction
In the past two decades acyclic nucleoside phosphonates
(ANPs) have become one of the most important classes of
antiviral drugs [1]. Three of them (adefovir, cidofovir,
tenofovir; Fig. 1) have been marketed for treatment of viral
infection caused by HIV, HBV, HSV and other DNA
viruses [2–5]. The concept of acyclic nucleosides is based
on the assumption that an acyclic moiety most often
bearing an oxygen atom mimics the furanose ring at least
partially. Acyclic nucleoside phosphonates require con-
version in vivo to their triphosphate metabolites to become
active [2, 6]. The replacement of the natural phosphate
moiety by a phosphonate group makes analogues less
susceptible to enzymatic hydrolysis [7, 8].
Further studies in this field brought a new generation of
nucleotide/nucleoside analogues in which natural nucleo-
bases were modified as exemplified by the 2,4-
diaminopyrimidine framework present in antiviral
HPMPO-DAPy and PMPO-DAPy [9–11] and the 1,2,4-
triazole ring in ribavirin (Fig. 2) [12].
The antiviral activity of ribavirin stimulated interest in
replacing the 1,2,4-triazole system with an isomeric 1,2,3-
triazole ring because several 1,2,3-triazoles exhibit anti-
bacterial [13–15], antifungal [15–17], anticancer [18–20],
anti-inflammatory [21, 22] and antiviral [23–26] properties.
It was found that carbocyclic analogues 1 and phospho-
nocarbocyclic analogues 2 of ribavirin displayed antiviral
activity against HIV-1 (Fig. 3) [27].
Furthermore, preliminary structure–activity relationship
evaluation of 1,2,3-triazole nucleoside phosphonates 3 and
4 suggested that this scaffold could be further optimised to
afford selective inhibitors of HCV replication (Fig. 4) [28].
On the other hand, it was reported that nucleoside ana-
logues 5 and 6 containing the 5,6-dihydro-1H-imidazo[4,5-
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d]pyridazine-4,7-dione ring instead of the natural purine
framework exhibited antiviral activity by inhibition of a
viral helicase from West Nile Virus (WNV) and HCV
(Fig. 5). These observations may be useful in designing a
lead structure for the development of new classes of anti-
viral agents [29].
Based on the active compounds already discussed, a
novel series of phosphonate analogues 11 having the 5,6-
dihydro-1H-[1,2,3]triazolo[4,5-d]pyridazine-4,7-dione sys-
tem was designed as potential antiviral agents (Scheme 1).
Furthermore, because their immediate precursor dihydraz-
ides 10 as well as diamides 9 share several common
structural features with ribavirin, they also may show
antiviral activity. The key step of our synthetic plan
involves the 1,3-dipolar cycloaddition of dimethyl acety-
lenedicarboxylate and x-azidoalkylphosphonates 7 which




The 1,2,3-triazoles 8a–8d and 8f were synthesised in
64–98 % yield employing the Huisgen 1,3-dipolar cyclo-
addition of the corresponding azidophosphonates 7 and
dimethyl acetylenedicarboxylate at 110 C in the same way
as the known compounds 8e and 8g [30, 31]. They were
finally purified either by chromatography on a silica gel
column or by crystallisation (Scheme 1).
The required azidoalkylphosphonates 7a–7e and 7g
have already been described in the literature [30, 32–36].
Azidophosphonate 7f was obtained in the Abramov reac-
tion [37, 38] from 3-azidopropanal [39] and diethyl
phosphite in 34 % yield (Scheme 2). It was found that
3-azidopropanal is unstable in the presence of triethyl-
amine used as a catalyst in this reaction. For this reason
only 0.4 equiv. of diethyl phosphite was applied to avoid
tedious separation of 7f from the reaction mixture.
The diamides 9a–9g were obtained from diesters 8a–8g
by ammonolysis according to a standard protocol
(Scheme 1) [6, 40]. The crude products were subjected to
column chromatography on silica gel and finally purified
Fig. 1 ANPs marketed for
treatment of viral infections
Fig. 2 Structures of HPMPO-DAPy, PMPO-DAPy and ribavirin
Fig. 3 Antiviral analogues of ribavirin having the 1,2,3-triazole ring
Fig. 4 1,2,3-Triazole nucleoside phosphonates as potential inhibitors
of HCV replication
Fig. 5 Cyclic nucleoside analogues based on the 5,6-dihydro-1H-
imidazo[4,5-d]pyridazine-4,7-dione framework
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by crystallisation to give 9a–9g in 37–61 % yields. The 1H
NMR spectra of diamides 9a–9g in chloroform-d con-
firmed the nonequivalence of protons from the carbamoyl
groups because in the 6.0–10.8 ppm region four broad
singlets were always observed.
The diesters 8a–8g were also converted to the corre-
sponding dihydrazides 10a–10g with hydrazine hydrate
(Scheme 1). Preliminary attempts at synthesising dihydra-
zide 10a followed the literature procedure [41] and showed
that refluxing phosphonate 8a and hydrazine hydrate in
ethanolic solution for 5 h led to the formation of several
products. The 31P NMR spectrum of the reaction mixture
revealed the presence of the expected phosphonate 10a
(76 %), bicyclic 1,2,3-triazolopyridazinedione 11a (11 %)
and their monodealkylated counterparts 12a and 13a (10
and 3 %, respectively) (Fig. 6). When hydrazinolysis of the
diester 8a was conducted for 2 h only phosphonates 10a
(79 %) and 11a (21 %) were produced. For this reason
syntheses of dihydrazides 10b–10g were performed under
the same conditions. However, it appeared that for com-
pounds 8c and 8g significant dealkylation still occurred. In
both cases the respective crude reaction mixtures contained
almost 50 % of by-products. Purifications on silica gel
columns and crystallisations gave dihydrazides 10a–10g in
28–66 % yields.
Finally, heating dihydrazides 10a–10g with 10 % hydro-
chloric acid for 2.5 h gave [1,2,3]triazolo[4,5-d]pyridazine-
4,7-diones 11a–11g (Scheme 1) in 30–66 % yields [41].
Conformational analysis
Detailed analyses of 1H and 13C NMR spectral data
revealed conformational preferences of phosphonates
described in this paper. Compounds 8a–11a contain an 1,2-
substituted ethylene fragment which does not freely rotate
around a C–C bond because their 1H NMR spectra display
AA0XX0P patterns. A similar spectrum was also noticed for
2-azidoethylphosphonate [31]. Antiperiplanar disposition
of the diethoxyphosphoryl groups and substituted 1,2,3-
triazoles 14a (Fig. 7) was proved by the presence of two
identical 3J(P–HX) = 10.5 Hz couplings which were cal-
culated from the 1H{31P} NMR spectrum of 8a.
In the 1H NMR spectra of compounds 8g, 10g, and 11g
three hydrogen atoms attached to the two-carbon linker
appeared as deceptively simple but very similar ABXP
spectral patterns. However, the relevant 3J(H1–H2a) and
3J(H1–H2b) coupling constants were precisely calculated
(10.2 and 3.6 Hz, respectively) from the 1H NMR spectrum
of diamide 9g. These values [42] together with small
couplings for 3J(P–H2a) and 3J(P–H2b) [43, 44] allowed us
to unequivocally establish 14g (Fig. 7) as the preferred
conformation of phosphonate 9g although other phospho-
nates from this series very likely adopt the same anti
conformation.
Scheme 1
Reagents and conditions: a. toluene, 110 °C, 4 h; b. aqueous ammonia, EtOH, rt, 24 h; 
c. hydrazine hydrate, EtOH, reflux, 2 h; d. 10% HCl, 90 °C, 2.5 h.
Scheme 2
Reagents and conditions: a. NaN3, acetic acid, -10 °C, 2 h; b. (EtO)2P(O)H, NEt3.
Fig. 6 Compounds 12a and 13a
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Large values (16.9–19.2 Hz) of 3J(P–CC–C3) [44–46]
observed in the 13C NMR spectra of phosphonates 8–11
containing a three-carbon fragment between the phospho-
rus atom and the 1,2,3-triazole ring (series b, e, and f)
evidenced the preference of antiperiplanar conformations
14b, 14e, and 14f (Fig. 7) for these compounds. This
conclusion was further supported by vicinal H1–H2 cou-
plings calculated for 2- and 1-hydroxyphosphonates (series
e and f) which clearly indicated gauche (3.0–3.6 Hz) and
anti (9.6–10.8 Hz) arrangements of the respective H–
C1C2–H protons.
Although values (9.3–12.1 Hz) of 3J(P–C–O–C) were
easily extracted from the 13C NMR spectra of phospho-
nates 8–11 (series c) they could not be unequivocally
applied in the estimation of the extent to which rotation
around the PC–OC bond is hindered because the angular
dependence of 3J(P–C–O–C) has not been established so
far. However, the rotation around the OC–CN bond is not
restricted because vicinal H2C–CH2 coupling constants
observed for phosphonates 8c–11c fall in the 4.8–5.2 Hz
range. On the other hand, on the basis of the values of
3J(HC–CH) found for PH2C–CH2O and OH2C–CH2N units
(7.2–7.8 and 5.1–5.7 Hz, respectively), full conformational
freedom within a five-atom linker in phosphonates 8–11
(series d) is anticipated.
Antiviral activity evaluation
The synthesised compounds 9a–9g, 10a–10g, and 11a–11g
were evaluated for their antiviral activities against a wide
variety of DNA and RNA viruses using the following cell-
based assays: (a) human embryonic lung (HEL) cell: herpes
simplex virus-1 (KOS), herpes simplex virus-2 (G), herpes
simplex virus-1 (TK- ACVr KOS), vaccinia virus, vesicular
stomatitis virus, varicella-zoster virus (TK? VZV strain
OKA and TK
¯
VZV strain 07-1) and cytomegalovirus
(CMV) (strain AD-169 and Davis); (b) CEM cell cultures:
human immunodeficiency virus-1 (HIV-1) and HIV-2;
(c) Vero cell cultures: para-influenza-3 virus, reovirus-1,
Sindbis virus, Coxsackie virus B4, Punta Toro virus;
(d) HeLa cell cultures: vesicular stomatitis virus, Coxackie
virus B4 and respiratory syncytial virus; (e) Crandel-Rees
feline kidney (CRFK) cell cultures: feline corona virus
(FIPV) and feline herpes virus (FHV) and (f) Madin Darby
Canine kidney (MDCK) cell culture: influenza A virus
H1N1 subtype A/PR/8, influenza H3N2 subtype A/HK/7/87
and influenza B virus (B/HK/5/72). Ganciclovir, cidofovir,
acyclovir, brivudin, (S)-9-(2,3-dihydroxypropyl)adenine
[(S)-DHPA], ribavirin, oseltamivir carboxylate, amantadine
and rimantadine were used as the reference compounds.
The antiviral activity was expressed as the EC50: the com-
pound concentration required to reduce virus plaques
formation (VZV, CMV) by 50 % or to reduce virus-induced
cytopathogenicity by 50 % (other viruses). None of the
compounds showed appreciable antiviral activity at sub-
toxic concentrations.
Evaluation of cytotoxicity
The cytotoxicity of the tested compounds towards the
uninfected host cells was defined as the minimum
cytotoxic concentration (MMC) that causes a micro-
scopically detectable alteration of normal cell
morphology. The 50 % cytotoxic concentration (CC50),
i.e. causing a 50 % decrease in cell viability, was
determined using a colorimetric 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay system. None of the tested
compounds affected the cell morphology of Vero, HEL,
HeLa or CRFK cells (MCC or CC50) at compound
concentrations up to 100 lM. They were also not cyto-
static against murine leukemia and human CEM and
HeLa cells at 100 lM.
Conclusions
Phosphonylated 1,2,3-triazoles 8a–8g were obtained in
good to excellent yields by 1,3-dipolar cycloaddition
between x-azidophosphonates 7a–7g and dimethyl acety-
lenedicarboxylate. New series of diamides 9a–9g,
dihydrazides 10a–10g and 1,2,3-triazolopyridazinediones
11a–11g were efficiently synthesised as phosphonate ana-
logues of acyclic nucleosides in which nucleobases were
replaced by substituted 1,2,3-triazoles.
Fig. 7 Preferred conformations
of the phosphonates described
in this study
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Compounds 8–11 (series a, b, e, f, g) exist in single
conformations in which diethoxyphosphoryl and substi-
tuted 1,2,3-triazolyl (series a and b) or (1,2,3-
triazolyl)methyl groups (series e, f, g) prefer the anti
orientation.
All synthesised compounds were evaluated for their
antiviral activity against DNA and RNA viruses and were
inactive. None of the compounds were cytotoxic (Vero,
HEL, HeLa) or cytostatic (L1210, CEM, HeLa) at a con-
centration up to 100 lM.
Experimental
The 1H NMR spectra were recorded in CDCl3, CD3OD or
D2O on the following spectrometers: Varian Mercury-300
and Bruker Avance III (600 MHz) with TMS as an internal
standard; chemical shifts d in ppm with respect to TMS;
coupling constants J in Hz. The 13C NMR spectra were
recorded for CDCl3, CD3OD or D2O solutions on Varian
Mercury-300 and Bruker Avance III (600 MHz) machines
at 75.5 and 150.5 MHz, respectively. The 31P NMR spectra
were recorded in CDCl3, CD3OD or D2O on Varian Mer-
cury-300 and Bruker Avance III (600 MHz) spectrometers
at 121.5 and 243 MHz, respectively.
IR spectra were measured on an Infinity MI-60 FT-IR
spectrometer. Melting points were determined on the
Boetius apparatus. Elemental analyses were performed by
the microanalytical laboratory of the host institution on
Perkin Elmer PE 2400 CHNS analyzer and the results were
found to be in good agreement (±0.3 %) with the calcu-
lated values.
The following absorbents were used: column chroma-
tography, Merck silica gel 60 (70–230 mesh); analytical
TLC, Merck TLC plastic sheets, silica gel 60 F254. TLC
plates were developed in chloroform–methanol solvent
systems. Visualization of spots was effected with iodine




A mixture of 5.77 g 3-azidopropanal [39] (0.0582 mol),
3.0 cm3 diethyl phosphite (0.023 mol) and 0.81 cm3 trieth-
ylamine (0.0058 mol) was stirred at 5 C for 24 h. The crude
product was subjected to chromatography on silica gel with
chloroform/methanol (100:1 and 50:1, v/v) to give a yellow
oil (4.671 g, 34 %). IR (film): V = 3,272, 2,985, 2,934,
2,911, 2,874, 2,102, 1,227, 1,028 cm-1; 1H NMR (CDCl3,
300 MHz): d = 1.35 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3),
1.87–2.06 (m, 3H, CH2, OH), 3.55 (t, J = 6.3 Hz, 2H,
CH2N3), 4.01 (dt, J = 9.8, 4.6 Hz, 1H, H-1), 4.12–4.24 (m,
4H, 2 9 POCH2CH3) ppm;
13C NMR (CDCl3, 75.5 MHz):
d = 16.6 and 16.7 (2 d, J = 5.4 Hz, POCC), 30.8 (d,
J = 2.6 Hz, C-2), 47.7 (d, J = 15.5 Hz, C-3), 62.9 and 63.2
(2 d, J = 7.2 Hz, POC), 64.6 (d, J = 164.6 Hz, C-1) ppm;
31P NMR (CDCl3, 121.5 MHz): d = 25.28 ppm.
Synthesis of 1,2,3-triazoles 8a–8g (general procedure)
A solution of azidophosphonate 7a–7g (1.00 mmol) and
dimethyl acetylenedicarboxylate 13 (1.00 mmol) in 4 cm3
toluene was refluxed for 4 h. The reaction mixtures were
concentrated to dryness to leave yellow oils which were
purified on silica gel columns with chloroform/methanol
(100:1, v/v) or were crystallised to give 1,2,3-triazoles 8a–8g.
Diethyl 2-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-
yl)ethylphosphonate (8a, C12H20N3O7P)
From 0.450 g azidophosphonate 7a (2.17 mmol) and
0.309 g dimethyl acetylenedicarboxylate 13 (2.17 mmol)
phosphonate 8a was obtained as a yellowish oil (0.674 g,
89 %) after chromatography on a silica gel column with
chloroform/methanol (100:1, v/v). IR (film): V = 3,462,
2,985, 2,958, 1,736, 1,468, 1,447, 1,225, 1,140, 1,060,
1,025, 957 cm-1; 1H NMR (CDCl3, 300 MHz): d = 1.33
(t, J = 7.1 Hz, 6H, CH3CH2OP), 2.40–2.52 (m, 2H, PCH2),
3.98 (s, 3H, OCH3), 4.02 (s, 3H, OCH3), 4.08–4.18 (m, 4H,
CH3CH2OP), 4.82–4.91 (m, 2H, CH2N) ppm;
13C NMR
(CDCl3, 75 MHz): d = 16.6 (d, J = 5.7 Hz, CCOP), 27.2
(d, J = 140.6 Hz, PC), 45.4 (s, PCCN), 52.9 (s, OCH3),
53.7 (s, OCH3), 62.4 (d, J = 6.3 Hz, CCOP), 129.8 and
140.2 (2 s, C=C), 158.6 and 160.4 (2 s, C=O) ppm; 31P
NMR (CDCl3, 121 MHz): d = 25.9 ppm.
Diethyl 3-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-
yl)propylphosphonate (8b, C13H22N3O7P)
From 0.785 g azidophosphonate 7b (3.565 mmol) and
0.507 g dimethyl acetylenedicarboxylate 13 (3.565 mmol)
phosphonate 8b was obtained as a yellowish oil (1.067 g,
83 %) after chromatography on a silica gel column with
chloroform/methanol (100:1, v/v). IR (film): V = 2,953,
2,836, 1,736, 1,463, 1,226, 1,030 cm-1; 1H NMR (CDCl3,
300 MHz): d = 1.34 (t, J = 7.1 Hz, 6H, CH3CH2OP),
1.72–1.84 (m, 2H, PCH2CH2), 2.16–2.31 (m, 2H, PCH2),
4.00 (s, 3H, OCH3), 4.03 (s, 3H, OCH3), 4.05–4.18 (m, 4H,
CH3CH2OP), 4.71 (t, J = 7.1 Hz, 2H, CH2N) ppm;
13C
NMR (CDCl3, 75 MHz): d = 16.5 (d, J = 6.0 Hz, POCC),
22.6 (d, J = 143.1 Hz, PC), 23.5 (d, J = 4.3 Hz, PCC),
50.4 (d, J = 16.9 Hz, PCCC), 52.7 (s, OCH3), 53.2 (s,
OCH3), 61.8 (d, J = 6.3 Hz, POC), 129.7 and 139.8 (2 s,
C=C), 158.6 and 160.3 (2 s, C=O) ppm; 31P NMR (CDCl3,
121 MHz): d = 30.7 ppm.
Diethyl 2-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-
yl)ethoxymethylphosphonate (8c, C13H22N3O8P)
From 1.027 g azidophosphonate 7c (4.330 mmol) and 0.615 g
dimethyl acetylenedicarboxylate 13 (4.330 mmol) phospho-
nate 8c was obtained as a yellowish oil (1.538 g, 93 %) after
chromatography on a silica gel column with chloroform/
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methanol (100:1, v/v). IR (film): V = 3,459, 2,983, 2,957,
2,908, 1,732, 1,462, 1,225, 1,117, 1,060, 1,027, 960 cm-1; 1H
NMR (CDCl3, 600 MHz): d = 1.31 (t, J = 7.0 Hz, 6H,
CH3CH2OP), 3.74 (d, J = 7.9 Hz, 2H, PCH2), 3.98 (s, 3H,
OCH3), 4.02 (s, 3H, OCH3), 4.02 (t, J = 5.2 Hz, 2H,
OCH2CH2N), 4.08–4.13 (m, 4H, CH3CH2OP), 4.86 (t,
J = 5.2 Hz, 2H, OCH2CH2N) ppm;
13C NMR (CDCl3,
75 MHz): d = 16.5 (d, J = 5.7 Hz, POCC), 49.8 (s, CN),
52.8 (s, OCH3), 53.5 (s, OCH3), 62.6 (d, J = 6.5 Hz, POCC),
65.2 (d, J = 164.7 Hz, PC), 71.0 (d, J = 9.3 Hz, PCOC),
131.0 and 139.6 (2 s, C=C), 158.8 and 160.3 (2 s, C=O) ppm;
31P NMR (CDCl3, 243 MHz): d = 20.04 ppm.
Diethyl 2-[2-(4,5-dimethoxycarbonyl-1H-1,2,3-triazol-1-yl)-
ethoxy]ethylphosphonate (8d, C14H24N3O8P)
From 0.647 g azidophosphonate 7d (2.68 mmol) and
0.382 g dimethyl acetylenedicarboxylate 13 (2.68 mmol)
phosphonate 8d (1.030 g, 98 %) was obtained as a
yellowish oil. The crude product was sufficiently pure
and was used in the next step without further purification.
IR (film): V = 3,459, 2,983, 2,957, 2,909, 1,736, 1,466,
1,229, 1,118, 1,063, 1,027, 963 cm-1; 1H NMR (CDCl3,
600 MHz): d = 1.32 (t, J = 7.1 Hz, 6H, CH3CH2OP),
2.00 (dt, J = 15.3, 7.7 Hz, 2H, PCH2), 3.63 (dt, J = 10.4,
7.7 Hz, 2H, PCH2CH2O), 3.82 (t, J = 5.2 Hz, 2H,
OCH2CH2N), 4.00 (s, 3H, OCH3), 4.01 (s, 3H, OCH3),
4.05–4.12 (m, 4H, CH3CH2OP), 4.82 (t, J = 5.2 Hz, 2H,
OCH2CH2N) ppm;
13C NMR (CDCl3, 150 MHz):
d = 16.3 (d, J = 5.7 Hz, POCC), 26.7 (d, J = 139.3 Hz,
PC), 49.8 (s, OCCN), 52.6 (s, OCH3), 53.3 (s, OCH3), 61.6
(d, J = 6.4 Hz, CCOP), 65.3 (s, PCC), 68.7 (s, OCCN),
131.4 and 139.5 (2 s, C=C), 159.1 and 160.3 (2 s,
C=O) ppm; 31P NMR (CDCl3, 243 MHz): d = 27.58 ppm.
Diethyl 1-hydroxy-3-(4,5-dimethoxycarbonyl-1H-1,2,3-
triazol-1-yl)propylphosphonate (8f, C13H22N3O8P)
From 0.560 g azidophosphonate 7f (2.36 mmol) and
0.335 g dimethyl acetylenedicarboxylate 13 (2.36 mmol)
phosphonate 8f (0.850 g, 95 %) was obtained as a white
amorphous solid after chromatography on a silica gel
column with chloroform/methanol (100:1, v/v). M.p.: 107–
109 C; IR (film): V = 3,420, 3,218, 3,081, 2,985, 2,878,
1,675, 1,451, 1,280, 1,223, 1,030, 970 cm-1; 1H NMR
(CDCl3, 300 MHz): d = 1.33 and 1.34 (2 t, J = 7.2 Hz,
6H, CH3CH2OP), 2.28–2.47 (m, 2H, PCCH2), 3.70 (dd,
J = 6.0, 5.1 Hz, 1H, OH), 3.84 (dddd, J = 10.5, 6.3, 6.0,
3.3 Hz, 1H, PCH), 3.98 (s, OCH3), 4.00 (s, OCH3),
4.10–4.22 (m, 4H, CH3CH2OP), 4.75–4.90 (m, 2H, CH2N)
ppm; 13C NMR (CDCl3, 75 MHz): d = 16.6 and 16.7 (2 d,
J = 5.4 Hz, CCOP), 31.9 (d, J = 3.2 Hz, PCC), 47.2 (d,
J = 16.3 Hz, PCCC), 52.8 (s, OCH3), 53.6 (s, OCH3), 63.0
and 63.3 (2 d, J = 7.3 Hz, CCOP), 64.6 (d, J = 164.2 Hz,
PC), 130.3 and 139.7 (2 s, C=C), 158.8 and 160.4 (2 s,
C=O) ppm; 31P NMR (CDCl3, 121 MHz): d = 23.5 ppm.
Synthesis of diamides 9a–9g (general procedure)
To a solution of the diester 8a–8g (1.00 mmol) in 14 cm3
ethanol 16 cm3 was added aqueous ammonia. The reaction
mixtures were stirred at room temperature for 24 h. Etha-
nol and excess ammonia were evaporated in vacuo.
Diamides 9a–9g were purified on silica gel columns with
chloroform/methanol or by crystallisation.
Diethyl 2-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)ethyl-
phosphonate (9a, C10H18N5O5P)
From 0.165 g diester 8a (0.472 mmol) diamide 9a was
obtained as a white amorphous solid (0.065 g, 42 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, 20:1, v/v) followed by crystallisation from
ethanol/diethyl ether. M.p.: 172–173 C; IR (KBr):
V = 3,428, 3,228, 3,113, 2,986, 2,932, 1,687, 1,451,
1,221, 1,023 cm-1; 1H NMR (CDCl3, 300 MHz):
d = 1.34 (t, J = 6.9 Hz, 6H, CH3CH2OP), 2.41–2.53 (m,
2H, PCH2), 4.09–4.21 (m, 4H, CH3CH2OP), 5.08–5.17 (m,
2H, CH2N), 6.01 (s, 2H, NH2), 7.58 (s, 1H, NH), 10.77 (s,
1H, NH) ppm; 13C NMR (CD3OD, 75 MHz): d = 16.8 (d,
J = 6.0 Hz, CCOP), 27.3 (d, J = 140.3 Hz, PC), 47.2 (s,
PCCN), 63.8 (d, J = 6.6 Hz, CCOP), 132.1 and 140.4 (2 s,
C=C), 160.3 and 165.2 (2 s, C=O) ppm; 31P NMR (CDCl3,
121 MHz): d = 26.5 ppm.
Diethyl 3-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)propyl-
phosphonate (9b, C11H20N5O5P)
From 0.114 g diester 8b (0.314 mmol) diamide 9b was
obtained as a white amorphous solid (0.070 g, 61 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, v/v) and crystallisation from ethanol. M.p.:
143–144 C; IR (KBr): V = 3,455, 3,270, 2,984, 2,909,
1,694, 1,629, 1,592, 1,454, 1,205, 1,018, 961 cm-1; 1H
NMR (CDCl3, 300 MHz): d = 1.31 (t, J = 6.9 Hz, 6H,
CH3CH2OP), 1.74–1.86 (m, 2H, PCH2CH2), 2.18–2.32 (m,
2H, PCH2), 4.04–4.16 (m, 4H, CH3CH2OP), 4.98 (t,
J = 6.9 Hz, 2H, CH2N), 6.13 (s, 1H, NH), 6.25 (s, 1H,
NH), 7.62 (s, 1H, NH), 10.79 (s, 1H, NH) ppm; 13C NMR
(CDCl3, 75 MHz): d = 16.7 (d, J = 6.6 Hz, CCOP), 23.0
(d, J = 141.9 Hz, PC), 23.8 (d, J = 4.3 Hz, PCC), 51.8 (d,
J = 19.2 Hz, PCCC), 62.0 (d, J = 6.6 Hz, CCOP), 130.7
and 138.7 (2 s, C=C), 158.6 and 163.7 (2 s, C=O) ppm;
31P NMR (CDCl3, 121 MHz): d = 31.4 ppm.
Diethyl [2-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)eth-
oxy]-methylphosphonate (9c, C11H20N5O6P)
From 0.280 g diester 8c (0.738 mmol) diamide 9c was
obtained as a white amorphous solid (0.139 g, 54 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, v/v). M.p.: 100–101 C; IR (KBr):
V = 3,361, 3,259, 3,110, 2,990, 2,959, 2,901, 1,689,
1,613, 1,454, 1,303, 1,219, 1,118, 1,048, 1,019, 967,
668 E. Bankowska et al.
123
943 cm-1; 1H NMR (CD3OD, 600 MHz): d = 1.29 (t,
J = 7.1 Hz, 6H, CH3CH2OP), 3.89 (d, J = 8.5 Hz, 2H,
PCH2), 4.06 (t, J = 5.2 Hz, 2H, OCH2CH2N), 4.06–4.10
(m, 4H, CH3CH2OP), 5.14 (t, J = 5.2 Hz, 2H, CH2N)
ppm; 13C NMR (CD3OD, 150 MHz): d = 15.3 (d,
J = 5.9 Hz, CCOP), 50.3 (s, CN), 62.8 (d, J = 6.5 Hz,
CCOP), 64.0 (d, J = 164.7 Hz, PC), 71.1 (d,
J = 11.9 Hz, PCOC), 131.0 and 139.0 (2 s, C=C), 159.1
and 163.9 (2 s, C=O) ppm; 31P NMR (CD3OD, 243 MHz):
d = 21.3 ppm.
Diethyl 2-[2-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)eth-
oxy]ethylphosphonate (9d, C12H22N5O6P)
From 0.264 g diester 8d (0.671 mmol) diamide 9d was
obtained as a white amorphous solid (0.090 g, 37 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, v/v) and crystallisation from ethyl acetate.
M.p.: 102–103 C; IR (KBr): V = 3,400, 3,306, 3,214,
2,986, 2,906, 1,672, 1,608, 1,453, 1,245, 1,109, 1,024,
961 cm-1; 1H NMR (CDCl3, 300 MHz): d = 1.31 (t,
J = 6.9 Hz, 6H, CH3CH2OP), 2.05 (dt, J = 15.3, 7.8 Hz,
2H, PCH2), 3.69 (dt, J = 11.1, 7.8 Hz, 2H, PCH2CH2O),
3.91 (t, J = 5.4 Hz, 2H, OCH2CH2N), 4.01–4.12 (m, 4H,
CH3CH2OP), 5.11 (t, J = 5.4 Hz, 2H, OCH2CH2N), 6.00
(s, 1H, NH), 6.07 (s, 1H, NH), 7.60 (s, 1H, NH), 10.77 (s,
1H, NH) ppm; 13C NMR (CDCl3, 75 MHz): d = 16.6 (d,
J = 6.0 Hz, CCOP), 26.9 (d, J = 139.1 Hz, PC), 51.0 (s,
OCCN), 61.9 (d, J = 6.3 Hz, CCOP), 65.0 (s, PCCO), 69.1
(s, OCCN), 130.9 and 139.7 (2 s, C=C), 158.7 and
163.7 (2 s, C=O) ppm; 31P NMR (CDCl3, 121 MHz):
d = 29.2 ppm.
Diethyl 3-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)-2-hy-
droxypropylphosphonate (9e, C11H20N5O6P)
From 0.145 g diester 8e (0.382 mmol) diamide 9e was
obtained as a white amorphous solid (0.060 g, 45 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, v/v) and crystallisation from methanol.
M.p.: 142–143 C; IR (KBr): V = 3,428, 3,308, 3,034,
2,988, 1,686, 1,667, 1,599, 1,443, 1,375, 1,293, 1,113,
1,083, 1,055, 1,029, 960 cm-1; 1H NMR (CD3OD,
300 MHz): d = 1.32 (t, J = 7.2 Hz, 6H, CH3CH2OP),
2.06 (ddd, J = 22.8, 15.3, 7.8 Hz, 1H, PCHaHb), 2.18
(ddd, J = 20.4, 15.3, 5.1 Hz, 1H, PCHaHb), 4.07–4.19 (m,
4H, CH3CH2OP), 4.37–4.50 (m, 1H, PCCH), 4.99 (dd,
J = 13.5, 8.1 Hz, 1H, PCCCHaHb), 5.02 (dd, J = 13.5,
4.2 Hz, 1H, PCCCHaHb) ppm;
13C NMR (CD3OD,
75 MHz): d = 16.9 (d, J = 6.3 Hz, CCOP), 32.3 (d,
J = 141.7 Hz, PC), 58.1 (d, J = 18.0 Hz, PCCC), 63.4
and 63.7 (2 d, J = 6.6 Hz, CCOP), 67.0 (d, J = 4.0 Hz,
PCC), 132.6 and 140.4 (2 s, C=C), 160.6 and 165.3 (2 s,
C=O) ppm; 31P NMR (CD3OD, 121 MHz):
d = 30.1 ppm.
Diethyl 3-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)-
1-hydroxypropylphosphonate (9f, C11H20N5O6P)
From 0.180 g diester 8f (0.475 mmol) diamide 9f was
obtained as a white amorphous solid (0.093 g, 56 %) after
crystallisation from methanol. M.p.: 179–180 C; IR
(KBr): V = 3,433, 3,319, 3,212, 2,974, 2,930, 2,874,
1,668, 1,605, 1,455, 1,399, 1,221, 1,167, 1,066, 1,014,
953 cm-1; 1H NMR (CD3OD, 300 MHz): d = 1.32 (t,
J = 7.2 Hz, 6H, CH3CH2OP), 2.13–2.28 (m, 1H,
PCCHaHb), 2.31–2.44 (m, 1H, PCCHaHb), 3.89 (ddd,
J = 10.5, 7.2, 3.0 Hz, 1H, PCH), 4.10–4.21 (m, 4H,
CH3CH2OP), 4.95–5.14 (m, 2H, CH2N) ppm; solubility of
9f in D2O or CD3OD was not sufficient to measure the
13C
NMR spectrum; 31P NMR (CD3OD, 121 MHz):
d = 25.4 ppm.
Diethyl 2-(4,5-dicarbamoyl-1H-1,2,3-triazol-1-yl)-1-hy-
droxyethylphosphonate (9g, C10H18N5O6P)
From 0.230 g diester 8g (0.630 mmol) diamide 9g was
obtained as a white amorphous solid (0.112 g, 53 %) after
chromatography on a silica gel column with chloroform/
methanol (20:1, v/v) and crystallisation from methanol.
M.p.: 200–202 C; IR (KBr): V = 3,431, 3,223, 3,081,
2,990, 2,847, 1,671, 1,599, 1,452, 1,393, 1,289, 1,225,
1,031, 979 cm-1; 1H NMR (CD3OD, 600 MHz): d = 1.39
and 1.40 (2 t, J = 7.2 Hz, 6H, CH3CH2OP), 4.22-4.29 (m,
4H, CH3CH2OP), 4.55 (ddd, J = 10.2, 9.9 Hz, 3.6 Hz, 1H,
PCH), 5.10 (ddd, J = 13.5, 10.2, 8.7 Hz, 1H, PCCHaHb),
5.22 (ddd, J = 13.5, 3.6, 3.1 Hz, 1H, PCCHaHb) ppm;
solubility of 9g in D2O and CD3OD was not sufficient to
measure the 13C NMR spectrum; 31P NMR (CD3OD,
243 MHz): d = 21.2 ppm.
Synthesis of dihydrazides 10a–10g (general procedure)
A solution of the diester 8a–8g (0.73 mmol) and 0.530 cm3
hydrazine hydrate (10.8 mmol) in 6 cm3 ethanol was
refluxed for 2 h. The reaction mixtures were concentrated
to give yellow oils or solids which were subjected to
chromatography on a silica gel column with chloroform/
methanol or crystallisation to obtain dihydrazides 10a–10g.
Diethyl 2-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-
yl]ethylphosphonate (10a, C10H20N7O5P)
From 0.115 g diester 8a (0.330 mmol) dihydrazide 10a
was obtained (0.070 g, 61 %) after chromatography on a
silica gel column with chloroform/methanol (50:1, 20:1,
10:1, v/v) as a white amorphous solid. M.p.: 84–86 C; IR
(KBr): V = 3,335, 3,282, 2,984, 2,932, 1,661, 1,606,
1,551, 1,491, 1,262, 1,223, 1,056, 1,020, 963 cm-1; 1H
NMR (CD3OD, 300 MHz): d = 1.32 (t, J = 6.6 Hz, 6H,
CH3CH2O), 2.48–2.59 (m, 2H, PCH2), 4.07–4.18 (m, 4H,
CH3CH2O), 5.03–5.14 (m, 2H, CH2N) ppm;
13C NMR
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(CD3OD, 75 MHz): d = 16.9 (d, J = 6.0 Hz, CCOP), 27.4
(d, J = 140.0 Hz, PC), 47.1 (s, PCCN), 63.8 (d,
J = 6.3 Hz, CCOP 9 2), 130.8 and 139.3 (2 s, C=C),
157.6 and 161.8 (2 s, C=O) ppm; 31P NMR (CD3OD,
121 MHz): d = 28.2 ppm.
Diethyl 3-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-
yl]propylphosphonate (10b, C11H22N7O5P)
From 0.170 g diester 8b (0.468 mmol) dihydrazide 10b
was obtained as a white amorphous solid (0.113 g, 66 %)
after chromatography on a silica gel column with chloro-
form/methanol (50:1, 20:1, 10:1, v/v). M.p.: 73–75 C; IR
(KBr): V = 3,300, 3,192, 2,983, 2,931, 1,656, 1,551,
1,209, 1,024, 969 cm-1; 1H NMR (CDCl3, 300 MHz):
d = 1.28 (t, J = 6.9 Hz, 6H, CH3CH2OP), 1.71–1.82 (m,
2H, PCH2CH2), 2.13–2.27 (m, 2H, PCH2), 4.00–4.13 (m,
4H, CH3CH2OP), 4.94 (t, J = 7.2 Hz, 2H, CH2N),
5.15–6.03 (brs, 6H, NHNH2) ppm;
13C NMR (CDCl3,
75 MHz): d = 16.7 (d, J = 6.0 Hz, CCOP), 22.9 (d,
J = 139.9 Hz, PC), 23.9 (d, J = 7.4 Hz, PCC), 51.8 (d,
J = 18.9 Hz, PCCC), 62.0 (d, J = 6.6 Hz, CCOP), 129.5
and 137.6 (2 s, C=C), 156.3 and 161.3 (2 s, C=O) ppm;
31P NMR (CDCl3, 121 MHz): d = 31.5 ppm.
Diethyl [2-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-
yl]ethoxy]methylphosphonate (10c, C11H22N7O6P)
From 0.430 g diester 8c (1.13 mmol) dihydrazide 10c was
obtained as a colourless oil (0.139 g, 32 %) after chroma-
tography on a silica gel column with chloroform/methanol
(50:1, 20:1, 10:1, v/v). IR (film): V = 3,326, 3,248, 2,985,
2,918, 2,890, 1,666, 1,544, 1,440, 1,300, 1,238, 1,117,
1,024, 968 cm-1; 1H NMR (CD3OD, 600 MHz): d = 1.28
(t, J = 7.0 Hz, 6H, CH3CH2OP), 3.89 (d, J = 8.5 Hz, 2H,
PCH2), 4.05–4.10 (m, 6H, CH3CH2OP and OCH2CH2N),
5.14 (t, J = 4.8 Hz, 2H, OCH2CH2N) ppm;
13C NMR
(CD3OD, 150 MHz): d = 15.3 (d, J = 5.5 Hz, CCOP),
50.2 (s, CN), 62.8 (d, J = 6.5 Hz, CCOP), 64.0 (d,
J = 164.9 Hz, PC), 71.1 (d, J = 11.9 Hz, PCOC), 129.9
and 137.9 (2 s, C=C), 156.5 and 160.5 (2 s, C=O) ppm;
31P NMR (CD3OD, 243 MHz): d = 21.4 ppm.
Diethyl 2-[2-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-
1-yl]ethoxy]ethylphosphonate (10d, C12H24N7O6P)
From 0.216 g diester 8d (0.549 mmol) dihydrazide 10d
was obtained as a white amorphous solid (0.128 g, 59 %)
after chromatography on a silica gel column with chloro-
form/methanol (50:1, 20:1, v/v) and crystallisation from
ethyl acetate. M.p: 95–96 C; IR (KBr): V = 3,300, 3,232,
2,983, 2,913, 2,827, 1,667, 1,545, 1,550, 1,252, 1,023, 966,
918 cm-1; 1H NMR (CDCl3, 300 MHz): d = 1.31 (t,
J = 7.2 Hz, 6H, CH3CH2OP), 2.03 (dt, J = 15.0, 7.5 Hz,
2H, PCH2), 3.69 (dt, J = 11.1, 7.5 Hz, 2H, PCH2CH2O),
3.91 (t, J = 5.7 Hz, 2H, OCH2CH2N), 4.01–4.13 (m, 4H,
CH3CH2OP), 4.20 (brs, 4H, NH2), 5.13 (t, J = 5.7 Hz, 2H,
OCH2CH2N), 8.81 (s, 1H, NH), 12.0 (s, 1H, NH) ppm;
13C
NMR (CDCl3, 75 MHz): d = 16.6 (d, J = 6.0 Hz, CCOP),
27.0 (d, J = 138.5 Hz, PC), 51.0 (s, OCCN), 61.9 (d,
J = 6.3 Hz, CCOP), 65.0 (s, PCCO), 69.1 (s, OCCN),
129.9 and 137.5 (2 s, C=C), 156.5 and 161.3 (2 s,
C=O) ppm; 31P NMR (CDCl3, 121 MHz): d = 28.5 ppm.
Diethyl 3-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-
yl]-2-hydroxypropylphosphonate (10e, C11H22N7O6P)
From 0.290 g diester 8e (0.764 mmol) dihydrazide 10e was
obtained as a white amorphous solid (0.140 g, 48 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, 20:1, v/v) and crystallisation from ethanol.
M.p.: 140–142 C; IR (KBr): V = 3,336, 3,275, 2,980,
2,930, 1,668, 1,578, 1,549, 1,443,1,260, 1,217, 1,067,
1,027, 957 cm-1; 1H NMR (CD3OD, 600 MHz): d = 1.34
and 1.35 (2 t, J = 7.1 Hz, 6H, CH3CH2OP), 2.12 (ddd,
J = 23.6, 15.4, 8.2 Hz, 1H, PCHaHb), 2.18 (ddd, J = 20.1,
15.4, 4.7 Hz, 1H, PCHaHb), 4.11–4.19 (m, 4H,
CH3CH2OP), 4.44–4.47 (m, 1H, PCCH), 4.96 (dd,
J = 13.4, 8.4 Hz, 1H, PCCCHaHb), 5.05 (dd, J = 13.4,
4.1 Hz, 1H, PCCCHaHb) ppm;
13C NMR (CD3OD,
150 MHz): d = 15.3 (d, J = 5.8 Hz, CCOP), 30.8 (d,
J = 141.6 Hz, PC), 56.4 (d, J = 17.3 Hz, PCCC), 61.9
and 62.2 (2 d, J = 6.5 Hz, CCOP), 65.6 (d, J = 3.6 Hz,
PCC), 130.1 and 137.9 (2 s, C=C), 156.7 and 160.6 (2 s,
C=O) ppm; 31P NMR (CD3OD, 243 MHz): d = 28.9 ppm.
Diethyl 3-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-
yl]-1-hydroxypropylphosphonate (10f, C11H22N7O6P)
From 0.262 g diester 8f (0.691 mmol) dihydrazide 10f was
obtained as a white amorphous solid (0.155 g, 60 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, 30:1, v/v). M.p.: 119–120 C; IR (KBr):
V = 3,316, 3,266, 3,160, 2,976, 2,930, 1,659, 1,572, 1,532,
1,249, 1,210, 1,072, 1,022, 955 cm-1; 1H NMR (CD3OD,
300 MHz): d = 1.31 (t, J = 7.5 Hz, 6H, CH3CH2OP),
2.13-2.29 (m, 1H, PCCHaHb), 2.31–2.44 (m, 1H,
PCCHaHb), 3.91 (ddd, J = 10.8, 7.8, 3.3 Hz, 1H, PCH),
4.09–4.21 (m, 4H, CH3CH2OP), 4.96–5.15 (m, 2H, CH2N)
ppm; 13C NMR (CD3OD, 75 MHz): d = 17.0 (d,
J = 5.4 Hz, CCOP), 33.4 (s, PCC), 48.4 (d, J = 18.9 Hz,
PCCC), 64.2 and 64.5 (d, J = 7.1 Hz, CCOP), 65.6 (d,
J = 166.7 Hz, PC), 130.9 and 139.2 (2 s, C=C), 157.7 and
161.8 (2 s, C=O 9 2) ppm; 31P NMR (CD3OD,
121 MHz): d = 25.5 ppm.
Diethyl 2-[4,5-bis(hydrazinocarbonyl)-1H-1,2,3-triazol-1-
yl]-1-hydroxyethylphosphonate (10g, C10H20N7O6P)
From 0.450 g diester 8g (1.23 mmol) dihydrazide 10g was
obtained as a white amorphous solid (0.128 g, 28 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, 30:1, v/v). M.p.: 149–152 C; IR (KBr):
V = 3,334, 3,207, 2,980, 2,930, 2,870, 1,668, 1,578, 1,449,
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1,217, 1,067, 1,028, 953 cm-1; 1H NMR (D2O, 600 MHz):
d = 1.31 (t, J = 7.0 Hz, 6H, CH3CH2OP), 4.18–4.24 (m,
4H, CH3CH2OP), 4.53–4.58 (m, 1H, PCH), 4.94–5.01 (m,
1H, PCCHaHb), 5.11–5.16 (m, 1H, PCCHaHb) ppm;
13C
NMR (D2O, 150 MHz): d = 15.7 (d, J = 4.6 Hz, CCOP),
51.9 (d, J = 11.2 Hz, PCCN), 64.7 and 64.8 (2 d,
J = 7.4 Hz, CCOP), 65.5 (d, J = 165.8 Hz, PC), 130.4
and 137.5 (2 s, C=C), 156.5 and 160.2 (2 s, C=O) ppm;
31P NMR (D2O, 243 MHz): d = 21.8 ppm.
Synthesis of 1,2,3-triazolopyridazinediones 11a–11g
(general procedure)
A mixture of the dihydrazide 10a–10g (0.50 mmol) and
5 cm3 10 % hydrochloric acid was heated at 90 C for
2.5 h. After concentration in vacuo, crude products were
purified on a silica gel column with chloroform/methanol
or crystallised from the appropriate solvent.
Diethyl 2-(4,7-dioxo-5,6-dihydro-1H-1,2,3-triazolo[4,5-
d]pyridazin-1-yl)ethylphosphonate (11a, C10H16N5O5P)
From 0.167 g dihydrazide 10a (0.478 mmol) compound
11a was obtained as a white amorphous solid (0.045 g,
30 %) after chromatography on a silica gel column with
chloroform/methanol (50:1, 20:1, 10:1, v/v) followed by
crystallisation from ethanol. M.p.: 198–200 C; IR (KBr):
V = 3,385, 2,922, 2,672, 1,687, 1,582, 1,460, 1,262, 1,214,
1,014, 1,019, 980 cm-1; 1H NMR (CD3OD, 300 MHz):
d = 1.28 (t, J = 6.6 Hz, 6H, CH3CH2OP), 2.58 (dt,
J = 14.7 Hz, J = 7.5 Hz, PCH2), 4.03–4.13 (m, 4H,
CH3CH2OP), 5.12 (dt, J = 12.6 Hz, J = 7.5 Hz, CH2N)
ppm; 13C NMR (CD3OD, 150 MHz): d = 17.5 (d,
J = 5.7 Hz, CCOP), 28.2 (d, J = 141.0 Hz, PC), 46.5 (d,
J = 3.0 Hz, PCCN), 64.7 (d, J = 6.6 Hz, CCOP), 131.3
and 141.8 (2 s, C=C), 152.0 and 154.6 (2 s, C=O) ppm;




From 0.055 g dihydrazide 10b (0.151 mmol) compound
11b was obtained as a white amorphous solid (0.033 g,
66 %) after chromatography on a silica gel column with
chloroform/methanol (50:1, 20:1, 10:1, v/v). M.p.: 148–
150 C; IR (KBr): V = 3,446, 3,074, 2,991, 2,960, 1,662,
1,555, 1,462, 1,294, 1,218, 1,032, 972, 805 cm-1; 1H NMR
(CD3OD, 300 MHz): d = 1.31 (t, J = 6.9 Hz, 6H,
CH3CH2OP), 1.84–1.95 (m, 2H, PCH2CH2), 2.24–2.38
(m, 2H, PCH2), 4.02–4.15 (m, 4H, CH3CH2OP), 4.93 (t,
J = 6.9 Hz, 2H, CH2N) ppm;
13C NMR (CD3OD,
75 MHz): d = 16.7 (d, J = 5.7 Hz, CCOP), 22.7 (d,
J = 141.9 Hz, PC), 23.9 (s, PCC), 50.5 (d, J = 18.5 Hz,
PCCC), 62.6 (d, J = 6.5 Hz, CCOP), 129.1 and 139.7 (2 s,
C=C), 150.5 and 152.7 (2 s, C=O) ppm; 31P NMR




From 0.090 g dihydrazide 10c (0.237 mmol) compound
11c was obtained as a white amorphous solid (0.043 g,
52 %) after chromatography on a silica gel column with
chloroform/methanol (50:1, 20:1, v/v). M.p.: 170–172 C;
IR (KBr): V = 3,348, 2,985, 2,930, 2,918, 1,658, 1,552,
1,420, 1,260, 1,070, 1,028, 975 cm-1; 1H NMR (CD3OD,
600 MHz): d = 1.25 (t, J = 7.0 Hz, 6H, CH3CH2OP),
3.89 (d, J = 8.5 Hz, 2H, PCH2), 4.01–4.04 (m, 4H,
CH3CH2OP), 4.16 (t, J = 5.1 Hz, 2H, OCH2CH2N), 5.09
(t, J = 5.1 Hz, 2H, OCH2CH2N) ppm;
13C NMR (CD3OD,
150 MHz): d = 15.2 (d, J = 5.7 Hz, CCOP), 49.2 (s, CN),
62.7 (d, J = 6.6 Hz, CCOP), 63.9 (d, J = 164.8 Hz, PC),
70.9 (d, J = 12.1 Hz, PCOC), 129.2 and 139.3 (2 s, C=C),
149.6 and 152.3 (2 s, C=O) ppm; 31P NMR (CD3OD,




From 0.165 g dihydrazide 10d (0.419 mmol) compound
11d was obtained as a white amorphous solid (0.087 g,
58 %) after chromatography on a silica gel column with
chloroform/methanol (50:1, 20:1, v/v) and crystallisation
from ethyl acetate/chloroform. M.p.: 134–135 C; IR
(KBr): V = 3,433, 2,974, 2,928, 2,872, 1,715, 1,645,
1,206, 1,113, 1,065, 1,026, 982, 952 cm-1; 1H NMR
(CDCl3, 300 MHz): d = 1.26 (t, J = 7.2 Hz, 6H,
CH3CH2OP), 2.07 (dt, J = 15.0, 7.2 Hz, 2H, PCH2), 3.73
(dt, J = 13.5, 7.5 Hz, 2H, PCH2CH2O), 3.96–4.10 (m, 6H,
CH3CH2OP and OCH2CH2N), 5.01 (t, J = 5.1 Hz, 2H,
OCH2CH2N), 10.49 (brs, 2H, NH) ppm;
13C NMR (CDCl3,
75 MHz): d = 16.6 (d, J = 6.3 Hz, CCOP), 26.8 (d,
J = 138.9 Hz, PC), 49.9 (s, OCCN), 62.2 (d, J = 6.5 Hz,
CCOP), 65.0 (s, PCCO), 68.8 (s, OCCN), 129.4 and 139.4
(2 s, C=C), 151.1 and 152.8 (2 s, C=O) ppm; 31P NMR




From 0.270 g dihydrazide 10e (0.719 mmol) compound
11e was obtained as a white amorphous solid (0.087 g,
39 %) after chromatography on a silica gel column with
chloroform/methanol (20:1, 10:1, v/v) and crystallisation
from water. M.p.: 168–170 C; IR (KBr): V = 3,476,
2,982, 2,932, 2,867, 1,655, 1,550, 1,427, 1,405, 1,256,
1,222, 1,108, 1,054, 957 cm-1; 1H NMR (D2O, 600 MHz):
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d = 1.30 and 1.31 (2 t, J = 6.1 Hz, 6H, CH3CH2OP), 2.25
(td, J = 16.1, 8.8 Hz, 1H, PCHaHb), 2.35 (td, J = 15.8,
3.2 Hz, 1H, PCHaHb), 4.10–4.17 (m, 4H, CH3CH2OP),
4.52–4.59 (m, 1H, PCCH), 4.91 (dd, J = 12.8, 9.2 Hz, 1H,
PCCCHaHb), 4.98 (dd, J = 12.8, 2.6 Hz, 1H, PCCCHaHb)
ppm; 13C NMR (D2O, 150 MHz): d = 15.6 (d,
J = 5.7 Hz, CCOP), 30.0 (d, J = 139.9 Hz, PC), 55.7 (d,
J = 17.8 Hz, PCCC), 63.5 and 63.6 (2 d, J = 6.4 Hz,
CCOP), 65.4 (d, J = 3.8 Hz, PCC), 130.1 and 140.1 (2 s,
C=C), 149.8 and 153.4 (2 s, C=O) ppm; 31P NMR (D2O,




From 0.163 g dihydrazide 10f (0.430 mmol) compound
11f was obtained as a white amorphous solid (0.086 g,
58 %) after chromatography on a silica gel column with
chloroform/methanol (50:1, 20:1, 10:1, v/v). M.p.: 66–
68 C; IR (KBr): V = 3,362, 2,987, 2,920, 1,666, 1,580,
1,449, 1,212, 1,050, 1,021, 970 cm-1; 1H NMR (CD3OD,
300 MHz): d = 1.32 (t, J = 7.2 Hz, 6H, CH3CH2OP),
2.19–2.28 (m, 1H, PCCHaHb), 2.31–2.44 (m, 1H,
PCCHaHb), 3.89 (ddd, J = 10.5, 7.2, 3.0 Hz, 1H, PCH),
4.10–4.21 (m, 4H, CH3CH2OP), 4.95–5.12 (m, 2H, CH2N)
ppm; 13C NMR (CD3OD, 75 MHz): d = 17.0 (d,
J = 5.4 Hz, CCOP), 33.3 (d, J = 4.0 Hz, PCC), 48.1 (d,
J = 16.2 Hz, PCCC), 64.2 and 64.5 (d, J = 6.9 Hz,
CCOP), 65.4 (d, J = 167.3 Hz, PC), 130.2 and 140.8
(2 s, C=C), 148.9 and 152.2 (2 s, C=O) ppm; 31P NMR




From 0.100 g dihydrazide 10g (0.274 mmol) compound
11g was obtained as a colourless oil (0.036 g, 40 %) after
chromatography on a silica gel column with chloroform/
methanol (50:1, 10:1, v/v). IR (film): V = 3,362, 2,988,
2,971, 1,667, 1,580, 1,212, 1,021 cm-1; 1H NMR (CD3OD,
600 MHz): d = 1.38 and 1.39 (2 t, J = 7.0 Hz, 6H,
CH3CH2OP), 4.23–4.29 (m, 4H, CH3CH2OP), 4.64–4.69
(m, 1H, PCH), 5.09–5.15 (m, 2H, CH2N) ppm;
13C NMR
(CD3OD, 150 MHz): d = 15.3 and 15.4 (d, J = 5.2 Hz,
CCOP), 51.3 (d, J = 11.6 Hz, PCCN), 63.3 and 63.5 (2 d,
J = 6.8 Hz, COP), 66.4 (d, J = 166.2 Hz, PC), 129.2 and
139.4 (2 s, C=C), 150.1 and 152.4 (2 s, C=O) ppm; 31P
NMR (CD3OD, 243 MHz): d = 20.5 ppm.
Assays for antiviral activity other than HIV
The compounds were evaluated against the following
viruses: herpes simplex virus type 1 (HSV-1) strain KOS,
thymidine kinase-deficient (TK-) HSV-1 KOS strain
resistant to ACV (ACVr), herpes simplex virus type 2
(HSV-2) strain G, cytomegalovirus (strains AD-169 and
Davis), varicella-zoster virus (VZV) (strains OKA and
YS), vaccinia virus Lederle strain, respiratory syncytial
virus (RSV) strain Long, vesicular stomatitis virus (VSV),
coxsackie b4 virus, parainfluenza 3, influenza virus A
(subtypes H1N1, H3N2), influenza virus B, reovirus-1,
Sindbis virus and Punta Toro virus. The antiviral assays
were based on inhibition of virus-induced cytopathicity or
plaque formation in human embryonic lung (HEL) fibro-
blasts, African green monkey cells (Vero), human
epithelial cervix carcinoma cells (HeLa) or MDCK. Con-
fluent cell cultures in microtiter 96-well plates were
inoculated with 100 CCID50 of virus (1 CCID50 being the
virus dose to infect 50 % of the cell cultures) or 20 or
100 plaque forming units (PFU) (for VZV and CMV,
respectively) in the presence of varying concentrations of
the test compounds. Viral cytopathicity or plaque forma-
tion was recorded as soon as it reached completion in the
control virus-infected cell cultures that were not treated
with the test compounds. Antiviral activity was expressed
as the EC50 or compound concentration required to reduce
virus-induced cytopathogenicity or viral plaque formation
by 50 %.
Anti-HIV activity assays
Inhibition of HIV-1(IIIB)- and HIV-2(ROD)-induced cy-
topathicity in CEM cell cultures was measured in
microtiter 96-well plates containing 3 9 105 CEM cells/
cm3 infected with 100 CCID50 of HIV per cm3 and con-
taining appropriate dilutions of the test compounds. After
4–5 days of incubation at 37 C in a CO2-controlled
humidified atmosphere, CEM giant cell (syncytium) for-
mation was examined microscopically. The EC50 (50 %
effective concentration) was defined as the compound
concentration required to inhibit HIV-induced giant cell
formation by 50 %.
Cytostatic activity assays
All assays were performed in 96-well microtiter plates. To
each well were added (5–7.5) 9 104 tumour cells and a
given amount of the test compound. The cells were
allowed to proliferate for 48 h (murine leukemia L1210
cells) or 72 h (human lymphocytic CEM and human
cervix carcinoma HeLa cells) at 37 C in a humidified
CO2-controlled atmosphere. At the end of the incubation
period, the cells were counted in a Coulter counter. The
IC50 (50 % inhibitory concentration) was defined as the
concentration of the compound that inhibited cell prolif-
eration by 50 %.
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